metaEvidence - overview


			deaths (OS)	progression or deaths (PFS)	RFS/DFS
mNSCLC - L1 - PDL1 positive metastatic/advanced NSCLC (mNSCLC) - 1st line (L1) mNSCLC - L1 - PDL1 positive
versus Standard of Care (SoC)
	atezolizumab alone vs. Standard of Care (SoC)	3	0.83 [0.65; 1.06], 1 RCT, I2=0% inconclusive result	0.77 [0.63; 0.94], 1 RCT, I2=0% unassessable degree of certainty	-
	cemiplimab vs. Standard of Care (SoC)	1	0.57 [0.42; 0.77], 1 RCT, I2=0% unassessable degree of certainty	0.54 [0.43; 0.68], 1 RCT, I2=0% unassessable degree of certainty	-
	durvalumab alone vs. Standard of Care (SoC)	1	0.76 [0.56; 1.03], 1 RCT, I2=0% inconclusive result	0.87 [0.59; 1.29], 1 RCT, I2=0% inconclusive result	-
	nivolumab alone vs. Standard of Care (SoC)	2	1.07 [0.86; 1.33], 1 RCT, I2=0% inconclusive result	1.17 [0.95; 1.44], 1 RCT, I2=0% inconclusive result	-
	pembrolizumab alone vs. Standard of Care (SoC)	4	0.74 [0.56; 0.97], 2 RCTs, I2=51% conclusive moderate degree of certainty	0.74 [0.35; 1.56], 2 RCTs, I2=95% inconclusive result	-